Sandra A. Boyd
Drug National Expert, Pharmaceutical Quality Program Branch
ORA (National Expert, Washington DC area)
Veteran 15-year FDA investigator and data integrity specialist — produces some of FDA's most detailed 483s (38+ pages) and splits time between performing inspections and training new investigators on sterile inspections and data integrity.
Inspection Approach
How Sandra Inspects
Sandra Boyd is one of FDA's designated Drug National Experts, a role that combines active field inspection work with training the next generation of investigators. Her 15-year career includes 4 years on the Dedicated Foreign Cadre with a 4-month assignment in China, giving her deep international manufacturing experience.
Her inspection approach is defined by meticulous examination of laboratory data, chromatographic audit trails, and the integrity of quality system records. She advocates for tying audit trail reviews directly to product release decisions — "to make sure that nothing happened, that each sample was only injected one time, and that there are no test injections." At Novel Laboratories (Lupin Somerset), she produced a 38-page 483 documenting stability programme deficiencies, inadequate OOS investigations (59 OOS lots released), and water system microbial testing failures.
Boyd specifically looks for repeat observations from prior inspections, making her return visits particularly consequential. She also reviews video recordings of aseptic operations for gowning compliance, technique, and behavioural adherence — a practice she brings from her training role where she teaches new investigators how to evaluate sterile processing.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
Novel Laboratories, Inc. dba Lupin Somerset
- Stability samples stored improperly — boxes, towels, and lining materials blocking airflow in stability chambers
- Approximately 59 OOS lots released for potency/reconstitution time failures without adequate investigation
- Water system microbial testing method not validated; action levels not based on historical data; microbial flora unknown
- Analytical methods lacked sample preparation accuracy verification and mass balance determination for specificity
- Extraneous peaks during equipment cleaning swab analysis not investigated — no scientific justification for integration thresholds
- Ralstonia pickettii found in water system without root cause investigation
- 38-page Form 483 — Warning Letter 613385 issued April 2023
Biocon Sdn Bhd
- Procedures to prevent microbiological contamination of sterile drug products not established or followed
- Poor aseptic behaviour observed during review of filling operation videos
- Smoke studies on aseptic fill line failed acceptance criteria — turbulent and non-unidirectional airflow patterns
- Inadequate validation of aseptic processes — 8-observation Form 483
Eli Lilly and Company
- Major biologics/drugs facility team inspection with 4 investigators
- Quality system and manufacturing observations at large-scale facility
Panacea Biotec Pharma Limited
- Co-investigated with Muna Algharibeh — 9 observations on aseptic processing and quality systems
- Personnel qualification and media fill simulation deficiencies
Pre-Inspection Preparation
How to Prepare
- 1 Conduct a thorough audit trail review of all HPLC/GC systems tied to product release — ensure no test injections, deleted data, or duplicate sample analyses.
- 2 Review all OOS/OOT investigations for scientific rigour, timeliness, and documented root causes — 59 OOS lots released without investigation is a landmark finding.
- 3 Ensure stability programme samples are stored correctly with proper airflow and documented chamber qualification records.
- 4 Verify that analytical method validation includes sample preparation accuracy checks and mass balance determination.
- 5 Document chromatographic integration procedures with clear, reproducible parameters — avoid arbitrary minimum area/height settings.
- 6 Ensure water system monitoring includes periodic microbial identification, not just count-based action-level triggers.
- 7 Prepare cleaning validation documentation covering extraneous peak investigations with scientific justification for thresholds.
- 8 Ensure all previous 483 observations have been fully addressed — Boyd specifically looks for repeat observations.
- 9 Review video surveillance of aseptic operations for gowning, technique, and behavioural compliance — she reviews filling operation videos.
- 10 Have smoke study documentation readily available with clear acceptance criteria and results demonstrating unidirectional airflow.
- 11 Prepare for lengthy, detailed 483s — Boyd's documentation is among the most comprehensive in FDA, running 38+ pages.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Sandra A. Boyd — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
